Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer

NCT07752550 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Triple-Negative Breast Cancer (TNBC)

Interventions

DRUG: Retlirafusp alfa+Nab-paclitaxel:
DRUG: Retlirafusp alfa+Fluzoparib
DRUG: Retlirafusp alfa+TP-AC
DRUG: Retlirafusp alfa+Fluzoparib

Sponsor

Harbin Medical University